ES2044941T3 - Estabilizacion de hormonas promotoras del crecimiento. - Google Patents
Estabilizacion de hormonas promotoras del crecimiento.Info
- Publication number
- ES2044941T3 ES2044941T3 ES87307406T ES87307406T ES2044941T3 ES 2044941 T3 ES2044941 T3 ES 2044941T3 ES 87307406 T ES87307406 T ES 87307406T ES 87307406 T ES87307406 T ES 87307406T ES 2044941 T3 ES2044941 T3 ES 2044941T3
- Authority
- ES
- Spain
- Prior art keywords
- growth promoting
- stabilization
- amino acids
- promoting hormones
- hormones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005556 hormone Substances 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 239000004381 Choline salt Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Deposition Of Substances Of Which Semiconductor Devices Are Composed (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Chemical Vapour Deposition (AREA)
- Saccharide Compounds (AREA)
Abstract
LAS HORMONAS DEL CRECIMIENTO PUEDEN SER MEZCLADAS CON VARIOS ESTABILIZADORES PARA MANTENER LA FORMACION DISMINUIDA DE INSOLUBLES Y LA CONSERVACION DE LA BIOACTIVIDAD SOLUBLE DE LA HORMONA QUE FOMENTA EL CRECIMIENTO EN AMBIENTES ACUOSOS. EJEMPLO DE TALES ESTABILIZADORES INCLUYEN CIERTOS POLIOLES, AMINOACIDOS, POLIMEROS DE AMINOACIDOS QUE TIENEN GRUPOS LATERALES CARGADOS DE PH FISIOLOGICOS Y SALES COLINAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP87307406A EP0303746B2 (en) | 1987-08-21 | 1987-08-21 | Stabilization of growth promoting hormones |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2044941T3 true ES2044941T3 (es) | 1994-01-16 |
ES2044941T4 ES2044941T4 (es) | 1996-07-16 |
ES2044941T5 ES2044941T5 (es) | 1999-02-16 |
Family
ID=8198005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES87307406T Expired - Lifetime ES2044941T5 (es) | 1987-08-21 | 1987-08-21 | Estabilizador de hormonas promotoras del crecimiento. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0303746B2 (es) |
AT (1) | ATE82506T1 (es) |
DE (1) | DE3782737T3 (es) |
ES (1) | ES2044941T5 (es) |
HU (1) | HU202117B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5122512A (en) * | 1988-09-12 | 1992-06-16 | Pitman-Moore, Inc. | Swine growth promoting composition |
US5384132A (en) * | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
US5270057A (en) * | 1990-03-20 | 1993-12-14 | Akzo N.V. | Stabilized gonadotropin containing preparations |
SE9002731D0 (sv) * | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product comprising growth factor |
DK204791D0 (da) * | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
US6022858A (en) * | 1991-12-20 | 2000-02-08 | Novo Nordisk A/S | Pharmaceutical formulation of human-growth hormone pretreated with zinc salt |
US5849700A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
AU4278393A (en) * | 1992-04-07 | 1993-11-08 | Mallinckrodt Veterinary, Inc. | Lyophilized somatotropin formulations |
CA2489978A1 (en) * | 1992-07-31 | 1994-02-17 | Genentech, Inc. | Human growth hormone aqueous formulation |
ES2153418T3 (es) * | 1993-02-23 | 2001-03-01 | Genentech Inc | Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes. |
US5652216A (en) * | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
WO1995035116A1 (en) * | 1994-06-17 | 1995-12-28 | Applied Research Systems | Hgh containing pharmaceutical compositions |
US5654278A (en) * | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
IL115592A (en) * | 1994-10-13 | 2000-07-26 | Novo Nordisk As | Stabilized pharmaceutical formulation comprising a growth hormone and leucine |
US5631225A (en) * | 1994-10-13 | 1997-05-20 | Novo Nordisk A/S | Pharmaceutical formulation |
US5547696A (en) * | 1994-10-13 | 1996-08-20 | Novo Nordisk A/S | Pharmaceutical formulation |
US5705482A (en) * | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US5552385A (en) * | 1995-06-05 | 1996-09-03 | Novo Nordisk A/S | Pharmaceutical formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
AUPN801296A0 (en) | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
US20070179096A1 (en) | 1996-04-24 | 2007-08-02 | Novo Nordisk A/S | Pharmaceutical Formulation |
ZA9711731B (en) | 1996-12-31 | 1998-07-01 | Monsanto Co | Aqueous glycerol formulations of somatotropin |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
BR0014486A (pt) | 1999-10-04 | 2002-09-17 | Chiron Corp | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado |
AU2001238540A1 (en) * | 2000-02-24 | 2001-09-03 | Monsanto Technology Llc | Non-aqueous injectable formulations for extended release of somatotropin |
WO2002000261A2 (en) | 2000-06-26 | 2002-01-03 | Monsanto Technology Llc | Surfactant-containing formulations for extended release of somatotropin |
US6664234B1 (en) | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
MXPA03001092A (es) | 2000-08-07 | 2003-09-25 | Nektar Therapeutics Al Corp | Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada. |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
EP1581251B1 (en) | 2002-12-31 | 2016-03-16 | Althea Technologies, Inc. | Human growth hormone crystals and methods for preparing them |
WO2004062689A1 (en) | 2003-01-08 | 2004-07-29 | Chiron Corporation | Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
ES2605022T3 (es) * | 2006-07-06 | 2017-03-10 | Daewoong Co., Ltd. | Una formulación líquida estable de la hormona del crecimiento humana |
AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
USRE47150E1 (en) | 2010-03-01 | 2018-12-04 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
ES2708989T3 (es) * | 2010-03-31 | 2019-04-12 | Stabilitech Biopharma Ltd | Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre |
US20130089912A1 (en) * | 2011-10-06 | 2013-04-11 | Gloria Elliott | Methods and compositions for the stabilization of biologic material |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
JP5487276B2 (ja) * | 2012-11-12 | 2014-05-07 | デウン カンパニー,リミテッド | ヒト成長ホルモンを含有する安定した液状製剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193917A3 (en) * | 1985-03-06 | 1987-09-23 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration |
US4670249A (en) * | 1985-04-12 | 1987-06-02 | International Minerals & Chemical Corp. | Growth-promoting compositions |
-
1987
- 1987-08-21 EP EP87307406A patent/EP0303746B2/en not_active Expired - Lifetime
- 1987-08-21 AT AT87307406T patent/ATE82506T1/de not_active IP Right Cessation
- 1987-08-21 DE DE3782737T patent/DE3782737T3/de not_active Expired - Fee Related
- 1987-08-21 ES ES87307406T patent/ES2044941T5/es not_active Expired - Lifetime
- 1987-09-28 HU HU874332A patent/HU202117B/hu not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0303746B2 (en) | 1998-12-02 |
EP0303746A1 (en) | 1989-02-22 |
ATE82506T1 (de) | 1992-12-15 |
ES2044941T5 (es) | 1999-02-16 |
HUT44706A (en) | 1988-04-28 |
DE3782737T3 (de) | 1999-05-20 |
EP0303746B1 (en) | 1992-11-19 |
HU202117B (en) | 1991-02-28 |
DE3782737D1 (de) | 1992-12-24 |
ES2044941T4 (es) | 1996-07-16 |
DE3782737T2 (de) | 1993-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2044941T4 (es) | Estabilizacion de hormonas promotoras del crecimiento. | |
DE3583518D1 (de) | Produktion von eiern. | |
PT82978B (pt) | Processo para a producao de hormonas de crescimento recombinantes bio-activas secas | |
DE68908802T2 (de) | Stabilisierte Enzymdispersion. | |
SE8505048L (sv) | Nutritionsemulsion med syretransporterande egenskaper | |
ES8607021A1 (es) | Soluciones de sales del acido lactico de los acidos piperazinil-quinolon- y piperazinil-azaquinolon-carboxilicos | |
HK1006154A1 (en) | Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis | |
PT87658A (pt) | Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet loesung enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin | |
IE883618L (en) | Injection solution of salt of thioctic acid | |
ATE114470T1 (de) | Behandlung von intraocularem druck mit einer synergistischen kombination zur ophthalmischen verwendung. | |
DE3777367D1 (de) | Hirudin-variante, deren verwendung und herstellung. | |
GR3006748T3 (es) | ||
FI98891B (fi) | Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi | |
ES557426A0 (es) | Un procedimiento para la preparacion de una sal de dobutamina y acido lactobionico. | |
EP0142597A3 (en) | Curative composition for buerger's disease | |
KR880008812A (ko) | 항균성 동결건조 제제 | |
ATE53491T1 (de) | Niedrig osmotisches hypokalorisches waessriges praeparat fuer die infusion. | |
DE3167839D1 (en) | Method for preparing n-(4-(((2,4-diamino-6-pteridinyl)-methyl)methylamino)benzoyl)glutamic acid | |
DE59100098D1 (de) | Parenteral applizierbares lagerbestaendiges immunstimulierendes praeparat, verfahren zu seiner herstellung und dessen verwendung. | |
DK538482A (da) | Humant leukocytinterferon | |
EP0260092A3 (en) | Optically active beta-amino acid derivatives and their salts, and processes for producing the same | |
ES8501982A1 (es) | Un procedimiento para obtener una composicion farmaceutica liofilizada a base de interferon y un aminoacido estabilizante. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 303746 Country of ref document: ES |
|
FG2A | Definitive protection |
Ref document number: 0303746 Country of ref document: ES |